2022 World Conference on Lung Cancer (ePosters)-EP08.01-069. A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs

EP08.01-069. A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs

Back to course

Pdf Summary

A retrospective study is being conducted to assess the efficacy of immune checkpoint rechallenge/retreatment in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously progressed on immune checkpoint inhibitors (ICIs). ICIs have shown significant clinical activity in thoracic tumors and are approved as first-line treatment for NSCLC without actionable oncogenic drivers. However, the role of ICIs in later lines of therapy for patients who have progressed after previous ICIs is still unclear. <br /><br />The study aims to retrospectively analyze data from patients with metastatic NSCLC who were rechallenged/retreated with ICIs after progression. The cohort will include patients treated at the Lausanne University Hospital between January 2016 and March 2022, who received ICIs as monotherapy or in combination with chemotherapy or dual ICIs. Patients with central nervous system metastasis will also be included. <br /><br />The primary objective of the study is to evaluate overall survival (OS) in these patients, while secondary objectives include evaluating progression-free survival (PFS), response rates, duration of response, time to progression, and toxicity. The study will also assess the correlation between outcomes and various clinical variables such as sex, age, smoking history, and genetic and immune parameters. <br /><br />Clinical data from medical records will be entered into an electronic case report form (eCRF) and source data verification will be performed. Descriptive statistics will be analyzed using built-in functions and Kaplan-Meier time-to-event analysis will be performed to assess the OS and PFS. <br /><br />With a median follow-up time of 6 years, this study aims to provide valuable insights into the efficacy of retreatment/rechallenge with ICIs in patients with metastatic NSCLC who have previously progressed on ICIs. Personalizing this therapy and identifying patients who can benefit from immune checkpoint rechallenge/retreatment are important goals in the field of clinical research.

Asset Subtitle

Nuria Neisy Mederos Alfonso

Meta Tag

Speaker Nuria Neisy Mederos Alfonso

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

retrospective study

efficacy

immune checkpoint rechallenge

retreatment

advanced non-small cell lung cancer

metastatic NSCLC

immune checkpoint inhibitors

progression

overall survival

progression-free survival